Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial (vol 28, pg 2092, 2022)

NATURE MEDICINE

卷 -, 期 -, 页码 -

NATURE PORTFOLIO

-

Biochemistry & Molecular Biology Cell Biology Medicine, Research & Experimental